M. Seymour

发表

Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative

J. Blay, M. Sydes, A. Benson, 2015, European journal of cancer.

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

C. Wilson, C. Boni, F. D. De Braud, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.

M. Parmar, P. Quirke, J. Allan, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intratumoral stromal morphometry predicts disease recurrence but not response to 5‐fluorouracil—results from the QUASAR trial of colorectal cancer

D. Treanor, D. Kerr, R. Gray, 2018, Histopathology.

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

Susan Richman, Phil Quirke, Gary Middleton, 2013, The Lancet. Oncology.

Factors predicting outcome for advanced gastroesophageal cancer in elderly patients receiving palliative chemotherapy.

P. Hall, P. McShane, M. Seymour, 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

Non-cancer medications for patients with incurable cancer: time to stop and think?

P. Hall, M. Seymour, S. Lord, 2010, The British journal of general practice : the journal of the Royal College of General Practitioners.

MLH1 −93G>A promoter polymorphism and risk of mismatch repair deficient colorectal cancer

D. Bishop, A. Cox, P. Quirke, 2008, International journal of cancer.

Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning

K. Sirinukunwattana, C. Hardy, U. McDermott, 2020, Gut.

Phase I a nd P harmacokinetic S tudy o f I ntravenous I rinotecan Plus O ral C iclosporin i n P atients W ith F luorouracil- Refractory M etastatic C olon C ancer

G. Hall, S. Joel, J. Chester, 2003 .

Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer.

G. Hall, S. Joel, J. Chester, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies

I. Nagtegaal, B. Ylstra, G. Meijer, 2014, Clinical Cancer Research.

Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia

Kris D. McCombe, M. Salto‐Tellez, P. Bankhead, 2020, British Journal of Cancer.

Biodiversity Protection Treaty

M. Slevin, P. Johnson, P. Wrigley, 1994, Environmental Health Perspectives.

A pharmacokinetic and pharmacodynamic study in vivo of human HT29 tumours using 19F and 31P magnetic resonance spectroscopy.

J. Griffiths, M. Leach, I. Judson, 1997, European journal of cancer.

Colorectal cancer: treatment of advanced disease.

M. Seymour, Matthew T. Seymour, 1998, Cancer treatment reviews.

The prevalence and outcomes of frailty in older cancer patients: a systematic review.

P. Selby, John B. Young, A. Clegg, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Concomitant medications in cancer patients: should we be more active in their management?

P. Hall, M. Seymour, S. Lord, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC).

T. Hickish, S. Gwyther, P. Quirke, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.

J. Barrett, M. Parmar, R. Stephens, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

6003 The correlation between Topoisomerase-I (Topo1) expression and outcome of treatment with capecitabine and irinotecan in advanced colorectal cancer (ACC) patients (pts) treated in the CAIRO study of the Dutch Colorectal Cancer Group (DCCG)

I. Nagtegaal, P. Quirke, M. Koopman, 2009 .

Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone

C. Punt, L. Vermeulen, P. Quirke, 2021, British Journal of Cancer.

Standing up for the sequential strategy

M. Seymour, 2008 .

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial

H. Wasan, R. Kaplan, T. Maughan, 2012, British Journal of Cancer.

The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer

E. Kaltenthaler, M. Marples, M. Seymour, 2006, British Journal of Cancer.

Lack of pharmacokinetic interaction between 5‐fluorouracil and oxaliplatin

S. Joel, M. Slevin, E. Chatelut, 2004, Clinical pharmacology and therapeutics.

Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer

D. Rea, M. Saunders, C. Twelves, 2003, British Journal of Cancer.

Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer

R. James, D. Hochhauser, M. Seymour, 2002, British Journal of Cancer.

Non‐operative management of the primary tumour in patients with incurable stage IV colorectal cancer

P. Guillou, M. Seymour, A. Sarela, 2001, The British journal of surgery.

Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer.

J. Chester, M. Seymour, J. Dent, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

A feasibility, pharmacokinetic and frequency-escalation trial of intraperitoneal chemotherapy in high risk gastrointestinal tract cancer.

S. Joel, M. Slevin, J. Chester, 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer

S. Paisley, P. Tappenden, M. Saunders, 2006, British Journal of Cancer.

Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.

S. M. Crawford, Julia M. Brown, A. Szubert, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Colorectal cancer peritoneal metastases: Biology, treatment and next steps.

N. West, M. Seymour, A. Quyn, 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.

C. Tournigand, D. Sargent, C. Punt, 2016, The Lancet. Oncology.

Sequential chemotherapy for advanced colorectal cancer: Should we ever start with a single cytotoxic agent?

C. Punt, M. Seymour, 2008 .

A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma

C. Topham, M. Seymour, D. Jackson, 2006, British Journal of Cancer.

Attitudes and practice in the management of metastatic colorectal cancer in Britain. Colorectal Cancer Working Party of the UK Medical Research Council.

J. Cassidy, S. Stenning, M. Seymour, 1997, Clinical oncology (Royal College of Radiologists (Great Britain)).

Short Report Intravenous Irinotecan Plus Oral Ciclosporin

N. Vasudev, M. Seymour, D. A. Anthoney, 2005 .

Intravenous irinotecan plus oral ciclosporin.

N. Vasudev, M. Seymour, D. A. Anthoney, 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

6LBA Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)

J. Cheadle, T. Maughan, D. Fisher, 2009 .

Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials

P. Quirke, J. Cheadle, G. Middleton, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

The CAIRO and FOCUS studies: which lesson is to be learned?

C. Punt, M. Koopman, M. Seymour, 2009, The oncologist.

Fluorouracil, oxaliplatin and CPT-11 (irinotecan), use and sequencing (MRC FOCUS): A 2135-patient randomized trial in advanced colorectal cancer (ACRC)

M. Seymour, 2005 .

Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.

K. Rufibach, R. Stupp, J. Bernhard, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Designing phase II trials in cancer: a systematic review and guidance

M. Buyse, W. Gregory, J. Brown, 2011, British Journal of Cancer.

Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection.

D. Sebag‐Montefiore, M. Seymour, D. A. Anthoney, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant bevacizumab in colon cancer: where did we go wrong?

M. Seymour, 2012, The Lancet. Oncology.

International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct.

A. Benson, D. Cunningham, J. Bridgewater, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

This is a repository copy of Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B

D. Sargent, C. Bokemeyer, J. Marshall, 2019 .

Use of Gene Expression Profiles to Distinguish Molecular Subtypes in Colorectal Cancer: Progression Toward Primetime.

M. Seymour, J. Seligmann, 2017, Journal of the National Cancer Institute.

FOCUS4: MAMS Trial Design in Action. Early Closure of FOCUS4-D (Pan-HER 1, 2 and 3 Inhibitor Versus Placebo) in Advanced Colorectal Cancer (aCRC) Patients, with Tumours Wildtype (WT) for KRAS, NRAS, BRAF and PIK3CA

R. Butler, P. Quirke, H. Wasan, 2017 .

Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.

M. Seymour, J. Ledermann, P. Leonard, 2001, The New England journal of medicine.

Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer.

P. Ellis, S. Johnston, I. Smith, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a randomised trial comparing ECF with MCF in advanced oesophago-gastric cancer

T. Hickish, A. Norman, M. Nicolson, 1999 .

A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO)

K. Last, M. Jones, P. Hall, 2017, British Journal of Cancer.

15LBA Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN)

J. Cassidy, T. Maughan, D. Fisher, 2009 .

Combined epiregulin (EREG) and amphiregulin (AREG) expression levels as a biomarker of prognosis and panitumumab benefit in RAS-wt advanced colorectal cancer (aCRC).

J. Barrett, P. Quirke, S. Tejpar, 2014 .

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.

Daniel J Sargent, Christophe Tournigand, Eduardo Diaz-Rubio, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Advanced colorectal cancer: which regimes should we recommend?

D. Kerr, M. Seymour, R. Midgley, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular Markers of Chemotherapy Toxicity in Colorectal Cancer

M. Seymour, M. Braun, 2011 .

Continuous vs intermittant chemotherapy for advanced colorectal cancer: preliminary results of the MRC cr06b randomised trial

D. Kerr, C. McArdle, R. Stephens, 2001 .

Preliminary results of a multicentre randomised trial comparing 3 chemotherapy regimens (De Gramont, Lokich and Raltitrexed) in metastatic colorectal cancer.

D. Kerr, C. McArdle, R. Stephens, 1999 .

Edinburgh Research Explorer Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning

K. Sirinukunwattana, U. McDermott, Chieh-Hsi Wu, 2020 .

Excess treatment related deaths and impaired quality of life show raltitrexed is inferior to infusional 5FU regimens in the palliative chemotherapy of advanced colorectal cancer (CRC): Final results of MRC CR06

D. Kerr, C. McArdle, R. Stephens, 2000 .

Evaluation of miR 31 3p as a biomarker of prognosis and panitumumab benefit in RAS-wt advanced colorectal cancer (aCRC): Analysis of patients (pts) from the PICCOLO trial.

P. Laurent-Puig, P. Quirke, D. Vernerey, 2015 .

Are we representing the true population in oncology trials?

P. Hall, M. Seymour, S. Lord, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Preliminary safety data from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or oesophagogastric junction (OGJ) adenocarcinoma.

D. Cunningham, G. Middleton, S. Stenning, 2010 .

Safety results from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or type II/III oesophagogastric junction (OGJ) adenocarcinoma.

D. Smith, D. Cunningham, W. Allum, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

University of Birmingham Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer

P. Quirke, J. Cheadle, G. Middleton, 2017 .

The international rare cancers initiative.

E. Trimble, D. Lacombe, J. Welch, 2014 .

Biennial Report on Carcinogens

M. Slevin, S. Joel, M. Seymour, 1994, Environmental Health Perspectives.

FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer.

D. Morton, M. Seymour, 2019, Journal of Clinical Oncology.

Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil.

D. Kerr, C. McArdle, J. Ledermann, 1995, Journal of Clinical Oncology.

6097 POSTER Ciclosporin in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer – Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification

S. Gwyther, G. Middleton, S. Richman, 2011 .

Epirubicin, cisplatin and oral UFT with leucovorin ('ECU'): a phase I-II study in patients with advanced upper gastrointestinal tract cancer.

M. Slevin, M. Seymour, D. Papamichael, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen.

T. Powles, S. Ebbs, H. Bonnefoi, 1996, British Journal of Cancer.

Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): Mature results of the MRC COIN trial.

J. Cheadle, T. Maughan, D. Fisher, 2010 .

International Rare Cancers Initiative (IRCI)

D. Lacombe, T. Trimble, Nicola Keat, 2013, Ecancermedicalscience.

S. Joel, M. Seymour, 2004 .

Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT

R. Butler, J. Graham, P. Quirke, 2022, Efficacy and Mechanism Evaluation.

Peritoneal cytology in colorectal cancer

M. Seymour, A. Banerjee, 1999, Diseases of the colon and rectum.

KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.

J. Barrett, P. Quirke, F. Elliott, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial

Richard J Stephens, Mahesh KB Parmar, M. Parmar, 2007, The Lancet.

Controlled trial of Iodosorb in chronic venous ulcers.

J. A. Fox, G. Venn, R. Cohen, 1985, British medical journal.

High hospital research participation and improved colorectal cancer survival outcomes: a population-based study

Amy Downing, Mahesh Parmar, David Sebag-Montefiore, 2016, Gut.

The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.

T. Hickish, A. Norman, M. Nicolson, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular Markers of Chemotherapy Response in Colorectal Cancer

M. Seymour, M. Braun, 2010 .

Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.

D. Kerr, J. Pignon, A. González-Neira, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Artificial Intelligence–Assisted Amphiregulin and Epiregulin IHC Predicts Panitumumab Benefit in RAS Wild-Type Metastatic Colorectal Cancer

J. Barrett, J. Pugh, U. Kurkure, 2021, Clinical Cancer Research.

Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning

K. Sirinukunwattana, C. Hardy, U. McDermott, 2020, Gut.

Image-based consensus molecular subtype classification (imCMS) of colorectal cancer using deep learning

Jens Rittscher, Clare Verrill, Susan Richman, 2019, bioRxiv.

Title: Image-based consensus molecular subtype classification (imCMS) of colorectal cancer using deep learning

Tomlinson, K. Sirinukunwattana, C. Hardy, 2019 .

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Harpreet Wasan, Tamas Hickish, Ayman Madi, 2011, The Lancet. Oncology.

Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer

R. Butler, J. Graham, P. Quirke, 2022, Clinical trials.

In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer

M. Salto‐Tellez, U. McDermott, P. Johnston, 2020, Clinical Cancer Research.

Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database.

D. Sargent, C. Bokemeyer, E. Van Cutsem, 2018, European journal of cancer.

Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.

D. Kerr, R. Gray, P. Quirke, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

D. Lambrechts, M. D. James, J. Bridgewater, 2011, The Lancet.

DCR1 promoter hypermethylation and response to irinotecan in metastatic colorectal cancer

J. Herman, I. Nagtegaal, B. Ylstra, 2016 .

Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper

M. Coleman, M. Piccart, V. Torri, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer.

T. Hickish, A. Norman, D. Cunningham, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of the Oxidative DNA Damage Repair Gene OGG1 in Colorectal Tumorigenesis

V. Moskvina, P. Quirke, P. Propping, 2013 .

Role of the oxidative DNA damage repair gene OGG1 in colorectal tumorigenesis.

V. Moskvina, P. Quirke, P. Propping, 2013, Journal of the National Cancer Institute.

Prediction of the response of colorectal cancer to systemic therapy.

P. Quirke, S. Richman, J. Adlard, 2002, The Lancet. Oncology.

Intra-tumoral Heterogeneity of KRAS and BRAF Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing

P. Quirke, S. Richman, C. Daly, 2011, Analytical cellular pathology.

HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials

J. Barrett, D. Kerr, R. Gray, 2016, The Journal of pathology.

Molecular markers of chemotherapeutic response and toxicity in colorectal cancer

P. Quirke, M. Seymour, M. Braun, 2007, Expert review of anticancer therapy.

The prevalence and outcomes of frailty in older cancer patients: a systematic review.

P. Selby, A. Clegg, M. Seymour, 2015 .

Failure to validate toxicity and outcome biomarkers from the FFCD 2000-05 trial in the MRC CR08 FOCUS trial.

J. Barrett, S. Richman, M. Seymour, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel.

J. Barrett, P. Quirke, S. Tejpar, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Investigating the poor outcomes of BRAF -mutant advanced colorectal cancer to develop practical treatment strategies

P. Quirke, J. Cheadle, G. Middleton, 2017 .

Prognostic value of thymidylate synthase (TS) expression on failure-free survival of fluorouracil-treated metastatic colorectal cancer patients.

M. Parmar, P. Quirke, S. Richman, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.

C. Tournigand, D. Sargent, M. Buyse, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A ‘modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer

S. Joel, J. Chester, M. Seymour, 2002, British Journal of Cancer.

Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial

M. Parmar, R. Butler, J. Graham, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer

C. Tournigand, M. Buyse, C. Bokemeyer, 2019, JAMA network open.

Balancing the efficacy and toxicity of chemotherapy in colorectal cancer

M. Seymour, M. Braun, 2011, Therapeutic advances in medical oncology.

Clinical research for rare cancers: is it a reality in the global regulatory landscape? The international rare cancer initiative

E. Trimble, D. Lacombe, A. Negrouk, 2014 .

International rare cancers initiative.

T. Trimble, Nicola Keat, A. Negrouk, 2013, The Lancet. Oncology.

Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.

D. Smith, D. Cunningham, W. Allum, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma

H. Grabsch, D. Alderson, A. Wotherspoon, 2019, JAMA oncology.

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer.

T. Hickish, A. Norman, M. Nicolson, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease.

M. Gore, M. Slevin, J. Mansi, 1994, British Journal of Cancer.

Unilateral facial swelling in a thyrotoxic patient

M. Seymour, A. Morton, 2017, British Medical Journal.

Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer.

C. Tournigand, D. Sargent, R. Stephens, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer

H. Grabsch, S. Grumett, P. Hall, 2021, JAMA oncology.

Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival

D. Kerr, I. Tomlinson, P. Newcomb, 2015, Clinical Cancer Research.

Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials.

T. Hickish, A. Norman, M. Nicolson, 2006, European journal of cancer.

Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer

J. Herman, I. Nagtegaal, B. Ylstra, 2017, Oncotarget.

Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer

J. Herman, I. Nagtegaal, B. Ylstra, 2017, Oncotarget.

Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial.

H. Grabsch, S. Grumett, P. Hall, 2019, Journal of Clinical Oncology.

Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program.

D. Sargent, R. Goldberg, L. Saltz, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.

David M. Thomas, D. Sargent, A. Bleyer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.

C. Tournigand, D. Sargent, C. Bokemeyer, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013.

D. Sargent, E. Van Cutsem, M. Aapro, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Intermittent versus continuous oxaliplatin-fluoropyrimidine (Ox-Fp) chemotherapy (CT) to first-line treatment of patients (pts) with advanced colorectal cancer (aCRC): Predictive factors (PF), quality of life (QL), and final efficacy results from the MRC COIN trial

J. Cassidy, T. Maughan, D. Fisher, 2010 .

Conceptual approaches to metastatic disease.

M. Seymour, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial

R. Butler, P. Quirke, H. Wasan, 2018 .

Leucovorin a nd F luorouracil W ith o r W ithout O xaliplatin as F irst-Line T reatment i n A dvanced C olorectal C ancer

C. Wilson, C. Boni, A. Figer, 2000 .

The Royal College of Physicians Simms Lecture, 6 December 2011: clinical research networks and the benefits of intensive healthcare systems.

P. Selby, R. Kaplan, M. Seymour, 2012, Clinical medicine.

Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial

Jacob G. Scott, H. J. Pearson, C. Fuller, 2012 .

A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary.

L. Assersohn, T. Hickish, A. Norman, 2003, European journal of cancer.

A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer.

T. Hickish, A. Norman, D. Cunningham, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.

R. Stephens, E. Van Cutsem, L. Saltz, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A pooled safety and efficacy analysis examining the effect of performance status (PS) on outcomes in nine first-line treatment (rx) trials (cts) of 6,286 patients (pts) with metastatic colorectal cancer (MCRC)

C. Tournigand, D. Sargent, R. Goldberg, 2007 .

Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis

J. Hecht, C. Bokemeyer, E. Van Cutsem, 2021, Therapeutic advances in medical oncology.

How can clinical research improve European health outcomes in cancer?

R. Stephens, A. Boaz, M. Lawler, 2019, Journal of Cancer Policy.

Research-intensive cancer care in the NHS in the UK.

M. Parmar, D. Stewart, R. Wilson, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.

N. Bansback, M. Seymour, S. Hummel, 2002, Health technology assessment.

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project

C. Tournigand, D. Sargent, R. Simes, 2018, Journal of the National Cancer Institute.

Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer.

J. Barrett, P. Quirke, S. Tejpar, 2016, JAMA oncology.

A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?

M. Parmar, G. Taylor, R. Butler, 2014, British Journal of Cancer.

Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring

M. Parmar, R. Butler, J. Graham, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO).

S. Gwyther, J. Bridgewater, J. Wagstaff, 2013, European journal of cancer.

Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer

T. Hickish, D. Cunningham, I. Chau, 2017, World journal of gastrointestinal oncology.

Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics.

M. Slevin, S. Joel, M. Seymour, 1994, British Journal of Cancer.

Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial

S. Laurberg, R. Gray, P. Quirke, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council.

D. Kerr, R. Stephens, J. Ledermann, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial

M. Parmar, H. Wasan, G. Middleton, 2011, The Lancet.

Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): An ARCAD study with individual patient data (IPD) on 10,962 pts.

C. Tournigand, D. Sargent, M. Buyse, 2014 .

Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer (FOCUS).

M. Parmar, P. Quirke, J. Allan, 2006, Journal of Clinical Oncology.

Prognostic value of early objective tumor response (EOTR) to first-line systemic therapy in metastatic colorectal cancer (mCRC): Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database.

C. Tournigand, D. Sargent, J. Hecht, 2013 .

Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer

M. Buyse, A. Piga, C. Köhne, 2001, British Journal of Cancer.

Capecitabine (Cap) and oxaliplatin (Ox) in elderly and/or frail patients with metastatic colorectal cancer: The FOCUS2 trial

H. Wasan, T. Maughan, R. Langley, 2007 .

Phase II study ofcontinuous infusional 5-fluorouracil withepirubicin and carboplatin (instead ofcisplatin) inpatients withmetastatic/local ly

H. Bonnefoi, W. Allum, M. Seymour, 1996 .

A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas.

M. Slevin, P. Johnson, P. Wrigley, 1991, British Journal of Cancer.

Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER 2-Positive Gastroesophageal Adenocarcinoma : A Randomized Phase 2 Clinical Trial

H. Grabsch, D. Alderson, W. Allum, 2019 .

Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial.

H. Grabsch, D. Alderson, W. Allum, 2019 .

Mutation Detection by Clonal Sequencing of PCR Amplicons and Grouped Read Typing is Applicable to Clinical Diagnostics

Lucy F. Stead, G. Taylor, P. Quirke, 2013, Human mutation.

Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer

J. Barrett, H. Hurwitz, P. Quirke, 2017, JAMA oncology.

Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen

J. Neoptolemos, J. Neoptolemos, P. Johnson, 1999, British Journal of Cancer.

The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS).

Mark J Sculpher, Andrea Manca, Christian Asseburg, 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

FOCUS 3: A study to determine the feasibility of molecular selection of therapy using K-RAS, B-RAF, and topo-1 in patients with advanced colorectal cancer (ACRC).

M. Parmar, Geraint T. Williams, R. Butler, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ultrasound assessment of residual abnormalities following primary chemotherapy for breast cancer.

I. Smith, E. Moskovic, M. Seymour, 1997, British Journal of Cancer.

Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer.

C. Bokemeyer, E. Van Cutsem, C. Punt, 2021, Journal of the National Cancer Institute.

InterAACT: An international multicenter open label randomized phase II advanced anal cancer trial comparing cisplatin (CDDP) plus 5-fluorouracil (5-FU) versus carboplatin (CBDCA) plus weekly paclitaxel (PTX) in patients with inoperable locally recurrent (ILR) or metastatic disease.

J. Welch, A. Benson, D. Cunningham, 2015 .

Recruitment of cancer patients to National Institute for Health research cancer research network portfolio studies between 2001 and 2011.

M. Parmar, P. Selby, R. Haward, 2012 .

The impact of young age on survival in patients with metastatic colorectal cancer: Analysis from the ARCAD Clinical Trials Program

D. Sargent, R. Goldberg, L. Saltz, 2013 .

Exploring the poor outcomes of BRAF mutant (BRAF mut) advanced colorectal cancer (aCRC): Analysis from 2,530 patients (pts) in randomized clinical trials (RCTs).

R. Butler, P. Quirke, J. Cheadle, 2015 .

Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial

D. Kerr, C. McArdle, R. Stephens, 2003, The Lancet.

Non‐operative management of the primary tumour in patients with incurable stage IV colorectal cancer

P. Guillou, M. Seymour, A. Sarela, 2001, The British journal of surgery.

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

T. Hickish, H. Wasan, T. Maughan, 2011, The Lancet. Oncology.

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial

R. Butler, P. Quirke, H. Wasan, 2017, The lancet. Gastroenterology & hepatology.

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF , PIK3CA , KRAS , and NRAS (FOCUS4-D): a phase 2–3 randomised trial

R. Butler, P. Quirke, H. Wasan, 2018 .

HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC)

J. Barrett, K. Owzar, H. Hurwitz, 2015 .

DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study

P. Quirke, S. Stenning, M. Seymour, 2002, The Lancet.

What can the molecular pathologist offer for optimal decision making?

P. Quirke, S. Richman, G. Hutchins, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Transformer-based biomarker prediction from colorectal cancer histology: A large-scale multicentric study

Jakob Nikolas Kather, P. A. van den Brandt, H. Grabsch, 2023, Cancer cell.

Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer.

G. Hall, S. Joel, J. Chester, 2003, Journal of Clinical Oncology.

545P Epidermal growth factor receptor (EGFR) copy number (CN) as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC)

J. Barrett, P. Quirke, F. Elliott, 2017 .

Choosing the right strategy based on individualized treatment effect predictions: combination versus sequential chemotherapy in patients with metastatic colorectal cancer

C. Punt, M. Koopman, F. Visseren, 2019, Acta oncologica.

Sequential chemotherapy for colorectal cancer.

M. Seymour, 2011, The Lancet Oncology.

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

T. Hickish, H. Wasan, T. Maughan, 2011, The Lancet. Oncology.

Association of topoisomerase-1 (Topo1) with the efficacy of chemotherapy in a randomized trial for advanced colorectal cancer patients (FOCUS).

M. Parmar, P. Quirke, P. Selby, 2006, Journal of Clinical Oncology.

Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.

T. Maughan, R. Kaplan, M. Seymour, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS

B. Jasani, J. Cheadle, H. Wasan, 2009 .

The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS).

M. Parmar, M. Sculpher, R. Stephens, 2012, Value in Health.

Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies

I. Nagtegaal, B. Ylstra, G. Meijer, 2014, Clinical Cancer Research.

KRAS and BRAF Mutational Status can be Accurately Determined on Diagnostic Tissue Biopsies: An Analysis of Matched Biopsy and Resection Material from Patients with Colon Cancer in the NCRI FOxTROT trial

R. Gray, B. Warren, P. Quirke, 2012 .

Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.

D. Kerr, J. Pignon, A. González-Neira, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Individual patient data (IPD) analysis of progression-free survival (PFS) versus overall survival (OS) as an endpoint for metastatic colorectal cancer (mCRC) in modern trials: Findings from the 16,700 patients (pts) ARCAD database.

D. Sargent, M. Buyse, C. Fuchs, 2013 .

C. Tournigand, D. Sargent, C. Punt, 2016, The Lancet. Oncology.

The CAIRO and FOCUS studies: which lesson is to be learned?

C. Punt, M. Koopman, M. Seymour, 2009, The oncologist.

Molecular markers and the prediction of prognosis and response to therapy in colon cancer

Matthew T. Seymour, Pl Barratt, Sally P. Stenning, 1999 .

International rare cancers initiative.

T. Trimble, Nicola Keat, A. Negrouk, 2013, The Lancet. Oncology.